Don Hayes1, Sylvester M Black2, Joseph D Tobias3, Benjamin T Kopp4, Stephen E Kirkby5, Heidi M Mansour6, Bryan A Whitson2. 1. Departments of (a)Pediatrics; Internal Medicine; Surgery; Section of Pulmonary Medicine. Electronic address: hayes.705@osu.edu. 2. Surgery. 3. Anesthesiology, The Ohio State University College of Medicine, Columbus, Ohio; Department of Anesthesiology and Pain Medicine, Nationwide Children's Hospital, Columbus, Ohio. 4. Departments of (a)Pediatrics; Section of Pulmonary Medicine. 5. Departments of (a)Pediatrics; Internal Medicine; Section of Pulmonary Medicine. 6. Skaggs Pharmaceutical Sciences Center, University of Arizona-Tucson College of Pharmacy, Tucson, Arizona.
Abstract
BACKGROUND: Varying results have been reported in the investigation of human leukocyte antigen (HLA) mismatching and bronchiolitis obliterans syndrome (BOS) after lung transplantation (LTx). METHODS: The UNOS database was queried for the period 1997 to 2013 to examine HLA mismatching and its association with BOS in LTx. RESULTS: Of 16,959 first-time adult LTx recipients, 16,854 were included in the univariate Cox analysis and Kaplan-Meier survival function evaluation, and 14,578 were included in multivariate Cox models. Multivariate Cox analysis showed that the number of total HLA mismatches was significantly associated with greater hazard of BOS (HR = 1.060; 95% CI 1.013 to 1.108; p = 0.011), as was the presence of 2 HLA-A mismatches, when compared with 0 or 1 mismatch at that locus (HR = 1.128; 95% CI 1.026 to 1.240; p = 0.012). These results were confirmed using competing-risks regression models that adjusted for death before BOS diagnosis. Multivariate Cox models identified no significant association with BOS hazard for HLA-B (HR = 1.014; 95% CI 0.914 to 1.126; p = 0.785) or HLA-DR (HR = 1.085; 95% CI 0.987 to 1.193; p = 0.090) mismatches. Higher body mass index was associated with increased risk for BOS, whereas older age was protective against BOS. Induction with alemtuzumab (HR = 0.343; 95% CI 0.252 to 0.467; p < 0.001) or basiliximab (HR = 0.862; 95% CI 0.758 to 0.980; p = 0.023) and longer ischemic time (HR = 0.909; 95% CI 0.877 to 0.942; p < 0.001) were associated with lower hazard of BOS. CONCLUSIONS: Total HLA mismatches are associated with increased risk for BOS, specifically at the A locus. Induction with alemtuzumab or basiliximab reduced the risk, whereas greater ischemic time appears to also be protective.
BACKGROUND: Varying results have been reported in the investigation of human leukocyte antigen (HLA) mismatching and bronchiolitis obliterans syndrome (BOS) after lung transplantation (LTx). METHODS: The UNOS database was queried for the period 1997 to 2013 to examine HLA mismatching and its association with BOS in LTx. RESULTS: Of 16,959 first-time adult LTx recipients, 16,854 were included in the univariate Cox analysis and Kaplan-Meier survival function evaluation, and 14,578 were included in multivariate Cox models. Multivariate Cox analysis showed that the number of total HLA mismatches was significantly associated with greater hazard of BOS (HR = 1.060; 95% CI 1.013 to 1.108; p = 0.011), as was the presence of 2 HLA-A mismatches, when compared with 0 or 1 mismatch at that locus (HR = 1.128; 95% CI 1.026 to 1.240; p = 0.012). These results were confirmed using competing-risks regression models that adjusted for death before BOS diagnosis. Multivariate Cox models identified no significant association with BOS hazard for HLA-B (HR = 1.014; 95% CI 0.914 to 1.126; p = 0.785) or HLA-DR (HR = 1.085; 95% CI 0.987 to 1.193; p = 0.090) mismatches. Higher body mass index was associated with increased risk for BOS, whereas older age was protective against BOS. Induction with alemtuzumab (HR = 0.343; 95% CI 0.252 to 0.467; p < 0.001) or basiliximab (HR = 0.862; 95% CI 0.758 to 0.980; p = 0.023) and longer ischemic time (HR = 0.909; 95% CI 0.877 to 0.942; p < 0.001) were associated with lower hazard of BOS. CONCLUSIONS: Total HLA mismatches are associated with increased risk for BOS, specifically at the A locus. Induction with alemtuzumab or basiliximab reduced the risk, whereas greater ischemic time appears to also be protective.
Authors: Hrishikesh S Kulkarni; Wida S Cherikh; Daniel C Chambers; Victoria C Garcia; Ramsey R Hachem; Daniel Kreisel; Varun Puri; Benjamin D Kozower; Derek E Byers; Chad A Witt; Jennifer Alexander-Brett; Patrick R Aguilar; Laneshia K Tague; Yuka Furuya; G Alec Patterson; Elbert P Trulock; Roger D Yusen Journal: J Heart Lung Transplant Date: 2018-09-25 Impact factor: 10.247
Authors: Daniel R Calabrese; Ping Wang; Tiffany Chong; Jonathan Hoover; Jonathan P Singer; Dara Torgerson; Steven R Hays; Jeffrey A Golden; Jasleen Kukreja; Daniel Dugger; Jason D Christie; John R Greenland Journal: JCI Insight Date: 2019-11-14
Authors: Deepak K Nayak; Fangyu Zhou; Min Xu; Jing Huang; Moriya Tsuji; Jinsheng Yu; Ramsey Hachem; Andrew E Gelman; Ross M Bremner; Michael A Smith; Thalachallour Mohanakumar Journal: Sci Transl Med Date: 2017-07-12 Impact factor: 17.956
Authors: Sung Woo Moon; Moo Suk Park; Jin Gu Lee; Hyo Chae Paik; Young Tae Kim; Hyun Joo Lee; Samina Park; Sun Mi Choi; Do Hyung Kim; Woo Hyun Cho; Hye Ju Yeo; Seung Il Park; Se Hoon Choi; Sang Bum Hong; Tae Sun Shim; Kyung Wook Jo; Kyeongman Jeon; Byeong Ho Jeong; Song Yee Kim Journal: Yonsei Med J Date: 2020-07 Impact factor: 2.759